iiinova — where your digital self keeps evolving

Patrick Bryant

@patrickbryant1.bsky.social

Assistant Professor at Stockholm University. Dedicated Scientist.

Patrick Bryant @patrickbryant1.bsky.social · 26/08/2026

Can molecular glues be designed rather than discovered by chance? We built EvoBind-multimer to design small (6-10 AAs) cyclic peptide glues directly from protein sequences. We validate de novo VHL-KRAS and VHL-BRD4 glues in cells and patient-derived tumoroids.

230

Reposted by Patrick Bryant

Simon Stael @simonstael.bsky.social · 05/04/2026

Job alert🚨 Postdoc (Computational Proteomics × Plant Immunity) 🌱 Join us to build a cross-species plant pan-terminome & study proteolysis in immunity with excellent collaborators: Bernhard Kuester, Mathias Wilhelm, @degradomics.bsky.social, Patrick Willems, @patrickbryant1.bsky.social Please RT 🙏

186

Patrick Bryant @patrickbryant1.bsky.social · 07/02/2026

Introducing The Structural History of Eukarya (SHE): The first proteome-scale phylogeny constructed entirely from 3D structure. We computed 300 trillion alignments across 1,542 species to map the tree of life. 🧵👇 (1/5)

28439

Patrick Bryant @patrickbryant1.bsky.social · 03/10/2025

The future of drug design is in AI. RareFoldGPCR: Agonist Design Beyond Natural Amino Acids. Paper: www.biorxiv.org/content/10.1... Code: github.com/patrickbryan...

020

Patrick Bryant @patrickbryant1.bsky.social · 09/09/2025

Update: RareFold 🧬 Our AI framework for protein design with 29 noncanonical AAs now shows designed binders (linear + cyclic) are non-immunogenic in patient-derived assays — paving the way for safe next-gen peptide therapeutics. 👉https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2

biorxiv.org

RareFold: Structure prediction and design of proteins with noncanonical amino acids

Protein structure prediction and design have traditionally been limited to the 20 canonicalamino acids. Expanding this space to include noncanonical amino acids (NCAAs) offers newopportunities for pro...

0276

Patrick Bryant @patrickbryant1.bsky.social · 22/07/2025

Our study where we develop EvoBind2: Design of linear and cyclic peptide binders from protein sequence information is now published! www.nature.com/articles/s42...

152

Patrick Bryant @patrickbryant1.bsky.social · 17/07/2025

Cool! Congrats @proteinator.bsky.social 🎉

020

Patrick Bryant @patrickbryant1.bsky.social · 06/07/2025

Now published: our study on human-pathogen protein-protein interactions! We identify 30 interactions with an expected TM-score ≥0.9, tripling the structural coverage in these networks. One novel interaction was validated with mass spectrometry. journals.plos.org/ploscompbiol...

240

Patrick Bryant @patrickbryant1.bsky.social · 09/06/2025

Our latest work is out: we designed dual GLP1R/GCGR agonists—cyclic peptides that activate both metabolic receptors, entirely from sequence alone. This has never been done before. www.biorxiv.org/content/10.1...

051

Patrick Bryant @patrickbryant1.bsky.social · 27/05/2025

You can also design in Colab now: colab.research.google.com/github/patri...

colab.research.google.com

Google Colab

082

Patrick Bryant @patrickbryant1.bsky.social · 25/05/2025

Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated. 📄 biorxiv.org/content/10.1... 💻 github.com/patrickbryan...

2194